Attovia Therapeutics
ATTO | NASDAQ
$14.72
-$0.41 (-2.71%)
At close: Nov 16, 2026, 4:00 PM ET
Attovia Therapeutics Company Profile
Company profile explainedCompany Profile
A clinical-stage biopharmaceutical company developing biotherapeutics for immune-mediated diseases using its ATTOBODY biologics platform. The company's lead candidate, ATTO-1310, targets interleukin-31 (IL-31), known as the 'itch cytokine,' for the treatment of chronic pruritic diseases including atopic dermatitis. Its pipeline also includes multi-specific candidates for other inflammatory diseases.
Key Executives
| Name | Position |
|---|---|
| Tao Fu | CEO, President & Director |
| Hangjun Zhan | Chief Technology Officer |
| Steven Chan | Chief Financial Officer |
| Bora Han | VP & Head of Preclinical Development |
| Hubert C. Chen | Chief Medical Officer |
| Petter Veiby | Chief Scientific Officer |
| Zaneta Odrowaz | Chief Business Officer, Treasurer & Secretary |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Oct 08, 2026 | 4/A | [Amend] Filing |
| Oct 08, 2026 | 4/A | [Amend] Filing |
| Oct 08, 2026 | 3/A | [Amend] Filing |
| Oct 08, 2026 | 3/A | [Amend] Filing |
| Sep 02, 2026 | 10-Q | Quarterly Report |
| Sep 02, 2026 | 8-K | Current Report |
| Aug 28, 2026 | 144 | Filing |
| Aug 28, 2026 | 4/A | [Amend] Filing |
| Aug 28, 2026 | 4/A | [Amend] Filing |
| Aug 13, 2026 | 4 | Filing |
Attovia Therapeutics
| Country | United States |
| IPO Date | Aug 5, 2026 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 44 |
| CEO | Tao Fu |
Contact Details
1091 Industrial Rd, Ste 310 San Carlos,
California 94070 United States
Stock Details
| Ticker Symbol | ATTO |
| Exchange | NASDAQ |
| Fiscal Year | n/a |
| Reporting Currency | USD |
| CIK Code | 0002058707 |
| CUSIP Number | 04987L102 |
| ISIN Number | US04987L1026 |
| SIC Code | 2836 |
Add to Watchlist
Select watchlists to add or remove ATTO